PFIZER INC.

Power's AI platform simplifies patient access to clinical trials, reducing recruitment delays and enhancing patient understanding, as highlighted at DPHARM Idol Disrupt 2024.

FDA approves Novartis' Kisqali for HR+/HER2- stage II and III early breast cancer, significantly expanding eligible patient population.

Bispecific antibodies, with two binding domains, offer targeted therapeutics and address co-administration challenges, gaining traction in biopharma. Initially approved for cancer, they now target various diseases, with 12 approved in the U.S. and more in development. Their dual action reduces patient burden and enhances treatment effects, potentially transforming therapeutic paradigms beyond oncology. The market is projected to grow significantly due to rising chronic disease incidence and technological advancements.

Long-term Phase II PHAROS trial data show Pfizer’s Braftovi (encorafenib) and Mektovi (binimetinib) combo sustained efficacy in BRAF V600E-mutant metastatic NSCLC, positioning it as a promising first-line therapy. The combination demonstrated a 75% objective response rate (ORR) in treatment-naïve patients, with a median duration of response (DoR) of 40 months and median progression-free survival (PFS) of 30.2 months. Safety profile consistent with previous findings, with common treatment-related adverse events (TRAEs) including nausea, diarrhea, and fatigue. The combo was approved by the FDA in October 2023 and the European Commission in August 2024.

The global erythropoietin drugs market is projected to grow at a CAGR of 3.8% from 2024 to 2034, reaching $14.3 billion by 2034. Advances in precision medicine, regulatory reforms for biosimilars, and telemedicine integration are driving market growth. Key players include Amgen, Roche, and Johnson & Johnson. Epoetin Alfa and biosimilars lead the market segments.

Immunotherapies like Keytruda celebrate 10 years, sparking debate on patient cure declarations. The psychedelics industry features key figures like Robin Carhart-Harris. Pfizer critiques Medicare's digital mental health app proposal. Senate aide Shawn Bishop, key in drug pricing policy, is departing. FDA drafts guidance for international cancer trials, emphasizing data applicability to U.S. patients.

PD-1 inhibition with pembrolizumab before and after surgery significantly improves 5-year overall survival (86.6% vs 81.7%) in high-risk early triple-negative breast cancer, according to KEYNOTE-522 trial results.

BMS-986365, a heterobifunctional ligand-directed degrader of WT AR, exhibits low intrinsic agonism and direct antagonism via ligand-binding domain occupancy, leading to deep AR pathway inhibition and resistance combat. It shows a favorable preclinical profile and interim clinical data, differentiating from Arvinas' AR degraders.

AllClinicalTrials.com unifies US clinical trial data, simplifying access for patients and researchers. Features include a pre-screener survey, advanced search filters, and real-time notifications for new trials. Successfully supported Moderna's Phase 3 COVID-19 vaccine trial recruitment.